Preclinical and early systemic lupus erythematosus. Issue 4 (August 2019)

• Record Type: Journal Article
• Authors: Gatto, Mariele; Saccon, Francesca; Zen, Margherita; Iaccarino, Luca; Doria, Andrea
• Is Part Of: Best practice & research. Volume 33:Issue 4(2019:Aug.)
• Publication Date: 2019-08
• Subjects: Biomarkers -- Early diagnosis -- Classification -- Hydroxychloroquine; Rheumatology -- Periodicals; Rheumatic Diseases -- Periodicals; Reumatologie; 616.723005
• DOI: 10.1016/j.berh.2019.06.004
• Languages: English
• ISSNs: 1521-6942

Abstract

Abstract: The challenge of early diagnosis and treatment is a timely issue in the management of systemic lupus erythematosus (SLE), as autoimmunity starts earlier than its clinical manifestations. Hence, growing efforts for stratification of patients according to the individual risk of developing specific clinical manifestations and/or predicting a better response to a given treatment have led to the proposal of several biomarkers, which require validation for use in clinical practice. In this viewpoint, we aim at distinguishing and discussing the features and the approach to asymptomatic immunological abnormalities potentially heralding the development of SLE, defined as preclinical lupus, and clinical manifestations consistent with SLE not yet fulfilling classification criteria, defined as early lupus. In case of preclinical SLE, careful surveillance using available screening tools is paramount, while patients with early lupus deserve an appropriate and timely diagnosis and, consequently, a proper treatment including hydroxychloroquine as the anchor drug.